Interesting comment by OrdinaryAverageGuy: “The FDA hasn't approved Reolysin and the if the market saw it coming the stock price would be much higher.” You are echoing CravenRaven’s last post. You and he strongly disagree with my assertions that TSX would be a fairer trading platform if institutional holdings were reported on the TSX website, like on the NASDAQ, and the OSC and Ontario MOF scrapped their support of IIROC. It’s a coincidence that you and he never debated these changes unless one considers name calling debating. It’s another coincidence that you and he have never commented on the increase of institutional holdings on the NASDQ by Canadian firms (Non-Canadian holdings are trivial). Are they two of you saying that institutional investors do not move the market compared to retail investors? Why would retail investors like you and CravenRaven object to more information and ending the era of investment bank self-regulation? Answer: you are not amateur retail investors but frauds hiding behind computer aliases.
Continue to post as you wish. The two of you have served my purpose to reappear and I thank you for your posts. I needed to refresh my position before I attacked your flanks. My previous absence was to conduct a futile frontal attack. It was a required step to document their positions.
To repeat principles from The Art of War, I have the moral high ground. My objective is to pierce the corporate veil of a Canadian stock market manipulation. A Public Inquiry will shed light on how the manipulation of ONC was maintained but will also raise other questions such as why business papers were not aware of the manipulation. Your flanks include US supervision, the internet, social media, and politics. Your weakness is arrogance because you can fool some of the people all of the time and all of the people some of the time but you cannot fool all of the people all of the time.
Excuse me while I take a timeout from posting to focus on my end game. There is urgency to position things before Oncolytics announces preliminary Stage 1 results of their head and neck pivotal trial in the coming days or weeks. Your continued posting to promote the stock price with its associated low market capitalization will be more difficult if the spread in the survival curves is significant since further patients will not close the gap and the FDA would be foolish to set the SPA target too high to discourage Oncolytics from continuing the pivotal trial. Your posts about Brad and other concerns justifying an unrealistic market capitalization will be interesting to read but I see no reason to debate them. If I catch the ear of influence on your flank, they can read them.
As for OrdinaryAverageGuy’s downside, it only occurs if he is identified. Readers can imagine it. What is harder to imagine is the downside to the organizations, corporations, and senior management involved in this stock manipulation. My upside is the proverbial 15 minutes of fame plus a few coins.
To retail investors – hold and buy Oncolytics.